<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082667</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 0249</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VICC-BRE-0249</secondary_id>
    <nct_id>NCT00082667</nct_id>
  </id_info>
  <brief_title>Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast</brief_title>
  <official_title>EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. It is not yet known whether surgery is more effective with or without gefitinib&#xD;
      in treating ductal carcinoma in situ.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery&#xD;
      works compared to surgery alone for the treatment of women with ductal carcinoma in situ of&#xD;
      the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare epidermal growth factor receptor (EGFR) pathway biomarker modulation in tissue&#xD;
           samples of women with ductal carcinoma in situ (DCIS) of the breast treated with&#xD;
           gefitinib vs placebo followed by local surgery.&#xD;
&#xD;
        -  Compare the effect of these regimens on cell turnover in vivo in EGFR-positive vs&#xD;
           EGFR-negative patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the efficacy of these regimens in estrogen-receptor (ER)-positive vs ER-negative&#xD;
           and in HER2-positive vs HER2-negative patients with DCIS.&#xD;
&#xD;
        -  Correlate levels of HER2 extracellular domain with biomarker modulation in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral gefitinib once daily for 7-14 days or until the day before&#xD;
           local surgery. Patients then undergo lumpectomy or mastectomy.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily for 7-14 days or until the day before&#xD;
           local surgery. Patients then undergo local surgery as in arm I.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 78 patients (39 per treatment arm) will be accrued for this&#xD;
      study within 1.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left VICC&#xD;
  </why_stopped>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare epidermal growth factor receptor (EGFR) pathway biomarker modulation in tissue samples of women with ductal carcinoma in situ (DCIS) of the breast treated with gefitinib vs placebo followed by surgery.</measure>
    <time_frame>at time of surgery, after 7-14 days of gefitinib</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of gefitinib vs. placebo, followed by surgery on cell turnover in vivo in EGFR-positive vs. EGFR-negative patients</measure>
    <time_frame>at time of surgery, after 7-14 days of gefitinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effects of gefitinib in ER-positive vs. ER-negative DCIS and in HER2-positive vs. HER2-negative DCIS</measure>
    <time_frame>at time of surgery, after 7-14 days of gefitinib</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlate levels of HER2 extracellular domain in ER-positive vs. ER-negative and in HER2-positive cs. HER2-negative patients</measure>
    <time_frame>at time of surgery, after 7-14 days of gefitinib</time_frame>
  </other_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <other_name>ZD 1839, Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <other_name>lumpectomy or mastectomy of the breast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ductal carcinoma in situ (DCIS) of the breast OR mammogram&#xD;
             highly suspicious for DCIS&#xD;
&#xD;
               -  No invasive disease&#xD;
&#xD;
               -  Not completely excised&#xD;
&#xD;
          -  Epidermal growth factor receptor (EGFR) positive (&gt; 10% of cells stained)&#xD;
&#xD;
          -  Planned lumpectomy or mastectomy within the next 2-4 weeks&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  35 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  SGOT ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT &lt; 1.5 times ULN&#xD;
&#xD;
          -  PT and PTT ≤ 1.5 times ULN&#xD;
&#xD;
          -  INR ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class I-IV heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No acute asthma&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Random blood sugar &lt; 2.5 times ULN&#xD;
&#xD;
          -  No known hypersensitivity to study drug or its excipients&#xD;
&#xD;
          -  No nonhealing wound or fracture&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell carcinoma, breast&#xD;
             carcinoma, or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No psychosis or severe depression&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior trastuzumab (Herceptin®)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 1 year since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 year since prior aromatase inhibitors&#xD;
&#xD;
          -  At least 1 year since prior antiestrogens or luteinizing hormone-releasing hormone&#xD;
             agonists or antagonists&#xD;
&#xD;
          -  No concurrent glucocorticoids&#xD;
&#xD;
          -  Concurrent oral contraceptives allowed&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 1 year since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior oncologic or other major surgery&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy (except alopecia)&#xD;
&#xD;
          -  More than 30 days since prior non-approved or investigational drugs&#xD;
&#xD;
          -  No prior definitive local therapy&#xD;
&#xD;
          -  No prior immunosuppressive therapy&#xD;
&#xD;
          -  No prior gefitinib&#xD;
&#xD;
          -  No other prior EGFR inhibitors&#xD;
&#xD;
          -  No other concurrent cytotoxic drugs&#xD;
&#xD;
          -  No concurrent warfarin for anticoagulation&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers, including any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Ethosuximide&#xD;
&#xD;
               -  Griseofulvin&#xD;
&#xD;
               -  Nafcillin&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Nevirapine&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
               -  Phenylbutazone&#xD;
&#xD;
               -  Primidone&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Rofecoxib&#xD;
&#xD;
               -  Sulfamethazine&#xD;
&#xD;
               -  Sulfinpyrazone&#xD;
&#xD;
               -  Troglitazone&#xD;
&#xD;
          -  No concurrent antiretroviral treatment for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayer Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2004</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Ingrid Mayer, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine; Clinical Director, Breast Cancer Program; Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>breast cancer in situ</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

